Navigation Links
Neuropathy Patients More Likely to Receive High-cost, Low-yield Screening Instead of More Effective Tests
Date:1/23/2012

ANN ARBOR, Mich., Jan. 23, 2012 /PRNewswire-USNewswire/ -- Researchers at the University of Michigan analyzed the tremendous cost of diagnosing peripheral neuropathy and found that less expensive, more effective tests are less likely to be used.

Almost one-quarter of patients receiving neuropathy diagnoses undergo high-cost, low-yield MRIs while very few receive low-cost, high-yield glucose tolerance tests, according to the study that will be published Jan. 23 in the Archives of Internal Medicine.

The research was led by Brian Callaghan, M.D., assistant professor of neurology at the University of Michigan Medical School.

Patients diagnosed with peripheral neuropathy typically are given many tests but physicians are highly variable in their approach, says Callaghan.

"We spend a lot of money to work up a diagnosis of neuropathy. The question is whether that money is well spent," Callaghan says.

For patients with peripheral neuropathy, the nerves that carry information to and from the brain don't work property. This commonly leads to tingling or burning in arms or legs and loss of feeling — and the symptoms can go from subtle to severe.

Diabetes is the most common cause of this type of nerve problem. Peripheral neuropathy is found in about 15 percent of those over age 40.

Researchers used the 1996-2007 Health and Retirement Study to identify individuals with a diagnosis of peripheral neuropathy. They focused on 15 relevant tests and examined the number and patterns of tests six months before and after the initial diagnosis.

"Our findings, that MRIs were frequently ordered by physicians, but a lower-cost glucose tolerance test was rarely ordered, show that there is substantial opportunity to improve efficiency in the evaluation of peripheral neuropathy," Callaghan says.

"Currently no standard approach to the evaluation of peripheral neuropathy exists. We need more research to determine an optim
'/>"/>

SOURCE University of Michigan Health System
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
9. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
10. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
11. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
(Date:12/24/2014)... Mass. , Dec. 23, 2014   ... ), a biopharmaceutical company developing therapeutic products for ... Medicines Agency (EMA) of the Marketing Authorization Application ... EMA recently granted the company,s request for accelerated ... EMA,s regulatory review time.   The ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... SANTA ROSA, Calif. , Feb. 16 Osseon Therapeutics ... Europe . The procedures were performed in Milan, Italy ... largest independent medical device distributor in Europe , Osseoplasty cases ... United Kingdom , Germany and Spain . ...
... , CRANBURY, N.J. , Feb. 16 ... the fourth quarter and full year 2009.  The Company also provided ... key strategic priorities for 2010.  Additionally, the Company stated that it ... completing enrollment for its Phase 3 study of Amigal ™ ...
Cached Medicine Technology:Osseon Launches in Europe 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 11
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... first time to date, research published in the October ... sought to determine the use of chemotherapy in ... encompassing all patient ages. Prior population-based studies have shown ... cancer patients receive chemotherapy treatment. These studies have previously ...
... Researchers from the Arkansas Epilepsy Program found treatment with ... compared with placebo, for patients with uncontrolled partial-onset seizures ... in Epilepsia , a journal published by Wiley-Blackwell ... Epilepsy affects up to 2% of the worldwide ...
... papillomavirus (HPV) DNA-based testing or visual inspection of the ... had a statistically significant reduction in high grade cervical ... according to a study published online Sept. 30 in ... In many developing countries, especially in ...
... of Health scientists could explain how Salmonella bacteria, a ... In a study published this week in the ... describe finding a reservoir of rapidly replicating Salmonella inside ... cells and are pushed from the epithelial layer by ...
... MEDFORD/SOMERVILLE, Mass.--Researchers from Tufts University School of Engineering and ... precursors to the potent anti-cancer compound Taxol in an ... The findings are significant steps on the way to ... to design new Taxol-like pharmaceuticals. The work ...
... Louisville School of Nursing has earned a $792,000 grant ... Health Resources and Services Administration to develop nursing informatics ... well as practicing nurses from University of Louisville Hospital. ... a tsunami of patient data in order to make ...
Cached Medicine News:Health News:New lung cancer research finds half of advanced lung cancer patients receive chemotherapy 2Health News:Adjunctive rufinamide reduces refractory partial-onset seizures 2Health News:HPV screen-and treat-intervention effective in cervical cancer prevention 2Health News:NIH scientists describe how salmonella bacteria spread in humans 2Health News:Researchers advance biosynthesis of potent anti-cancer drug Taxol 2Health News:UofL School of Nursing awarded grant to fund new informatics education project 2
... with blade. Fiberoptic blades are designed ... allowing you to take advantage of ... from different fitting fiberoptic systems. FOCS™ ... cost effective alternative to expensive fiberoptic ...
... can be used with Portex® reusable or ... blades with long-lasting bronze fiber-optic bundles provide ... routine use., ,The laryngoscope blades are ... from infant to large adult, and in ...
... system. Providing an unobstructed view of the ... many types of intubations., ,A high ... patented Glidescope blade. Clear images are captured ... monitor screen. An LED light source mounted ...
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
Medicine Products: